Market Overview:
The global oclacitinib market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in the market can be attributed to factors such as rising prevalence of cancer, increasing demand for targeted therapies, and growing investments by pharmaceutical companies in R&D for novel oncology drugs. Based on type, the global oclacitinib market can be segmented into min purity less than 98%, min purity 98%-99%, and min purity more than 99%. The min purity less than 98% segment is expected to account for the largest share of the global oclacitinib market in 2018. This segment is also projected to grow at a CAGR of XX% during the forecast period. By application, research accounted for the largest share of the global oclacitinib market in 2017 and this trend is expected to continue duringthe forecast period. However, medical applications are projectedto grow at a higher CAGRduringthe forecastperiod owingto their growing use incancer treatment regimens across different geographies. .
Product Definition:
Oclacitinib is a drug used to treat canine atopic dermatitis, which is a skin disease caused by allergies. Oclacitinib blocks the action of a protein called JAK3, which is involved in the immune response that leads to inflammation. By blocking JAK3, oclacitinib reduces inflammation and relieves symptoms of atopic dermatitis.
Min Purity Less Than 98%:
Min Purity Less Than 98% is a new term in the Oclacitinib market. It means that the final product has to have less than 98% of purity (by weight) of the active ingredient, which is then used for treating cancer.
Min Purity 98%-99%:
Min Purity 98%-99% is a new generation of high purity small molecule intermediates. It has been developed to support the development of novel therapeutics with different properties and structures. The product is manufactured by GPCRPlc, a U.K.-based company that develops and manufactures drug-development solutions for the pharmaceutical industry, which includes high purity compounds at low cost with no compromise in terms of quality or efficacy.
Application Insights:
The research application segment led the global oclacitinib market in 2017 and is anticipated to maintain its dominance over the forecast period. Owing to extensive product portfolio, presence of key players and high R&D investments by companies for introduction of novel drugs, this segment is expected to continue leading over the next eight years.
Medical application was the second largest revenue-generating segment in 2017 owing to increasing usage of oclacitinib products for treating cancer pain. Moreover, increasing number of clinical trials with various cancer types being part of OAK Oncology program are further expected to propel growth during this study period.
Owing to growing prevalence rate and treatment failures associated with chronic conditions such as diabetes mellitus type 2 & 3 across regions; medical applications are anticipated grow at a significant rate during future period thereby contributing toward a substantial share within near future time frame.
Regional Analysis:
North America dominated the global market in 2017. The presence of key companies and well-established healthcare infrastructure are some factors responsible for its large share. In addition, increasing number of R&D activities to develop novel therapies is expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising disposable income, improving economic conditions, expanding population base and rising awareness about early diagnosis among patients in emerging countries such as China and India. Moreover, government initiatives encouraging domestic production are likely to support oclacitinib demand over the next eight years (2018– 2030).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the oclacitinib market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the United States in 2017. This number is expected to rise to 1,788,460 by 2020. This rising incidence of cancer is expected to drive demand for oclacitinib and other anticancer drugs in the coming years.
- Growing awareness about anticancer drugs: The growing awareness about anticancer drugs among patients and healthcare professionals is another key growth driver for the oclacitinib market. There has been a growing focus on targeted therapies in recent years due to their better efficacy and fewer side effects as compared to traditional chemotherapy regimens. Oclacitinib belongs to this category of targeted therapies and its increasing adoption can be attributed to this trend.
Scope Of The Report
Report Attributes
Report Details
Report Title
Oclacitinib Market Research Report
By Type
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
By Application
Research, Medical
By Companies
Cayman Chemical, Toronto Research Chemicals, Taiclone, BioVision, Adooq Bioscience, APExBIO Technology, BOC Sciences, TargetMol, BioVision, MyBiosource, Biosynth Carbosynth, Clearsynth, Selleck Chemicals, MedKoo, CSNpharm, LifeSpan BioSciences, J&K Scientific
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
166
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Oclacitinib Market Report Segments:
The global Oclacitinib market is segmented on the basis of:
Types
Min Purity Less Than 98%, Min Purity 98%-99%, Min Purity More Than 99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Research, Medical
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Cayman Chemical
- Toronto Research Chemicals
- Taiclone
- BioVision
- Adooq Bioscience
- APExBIO Technology
- BOC Sciences
- TargetMol
- BioVision
- MyBiosource
- Biosynth Carbosynth
- Clearsynth
- Selleck Chemicals
- MedKoo
- CSNpharm
- LifeSpan BioSciences
- J&K Scientific
Highlights of The Oclacitinib Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Min Purity Less Than 98%
- Min Purity 98%-99%
- Min Purity More Than 99%
- By Application:
- Research
- Medical
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Oclacitinib Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Oclacitinib is a drug used to treat advanced renal cell carcinoma (RCC). It works by blocking the growth of cancer cells.
Some of the major players in the oclacitinib market are Cayman Chemical, Toronto Research Chemicals, Taiclone, BioVision, Adooq Bioscience, APExBIO Technology, BOC Sciences, TargetMol, BioVision, MyBiosource, Biosynth Carbosynth, Clearsynth, Selleck Chemicals, MedKoo, CSNpharm, LifeSpan BioSciences, J&K Scientific.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Oclacitinib Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Oclacitinib Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Oclacitinib Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Oclacitinib Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Oclacitinib Market Size & Forecast, 2020-2028
4.5.1 Oclacitinib Market Size and Y-o-Y Growth
4.5.2 Oclacitinib Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Min Purity Less Than 98%
5.2.2 Min Purity 98%-99%
5.2.3 Min Purity More Than 99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Research
6.2.2 Medical
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Oclacitinib Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Oclacitinib Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Min Purity Less Than 98%
9.6.2 Min Purity 98%-99%
9.6.3 Min Purity More Than 99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Research
9.10.2 Medical
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Min Purity Less Than 98%
10.6.2 Min Purity 98%-99%
10.6.3 Min Purity More Than 99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Research
10.10.2 Medical
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Min Purity Less Than 98%
11.6.2 Min Purity 98%-99%
11.6.3 Min Purity More Than 99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Research
11.10.2 Medical
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Min Purity Less Than 98%
12.6.2 Min Purity 98%-99%
12.6.3 Min Purity More Than 99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Research
12.10.2 Medical
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Min Purity Less Than 98%
13.6.2 Min Purity 98%-99%
13.6.3 Min Purity More Than 99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Research
13.10.2 Medical
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Oclacitinib Market: Competitive Dashboard
14.2 Global Oclacitinib Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Cayman Chemical
14.3.2 Toronto Research Chemicals
14.3.3 Taiclone
14.3.4 BioVision
14.3.5 Adooq Bioscience
14.3.6 APExBIO Technology
14.3.7 BOC Sciences
14.3.8 TargetMol
14.3.9 BioVision
14.3.10 MyBiosource
14.3.11 Biosynth Carbosynth
14.3.12 Clearsynth
14.3.13 Selleck Chemicals
14.3.14 MedKoo
14.3.15 CSNpharm
14.3.16 LifeSpan BioSciences
14.3.17 J&K Scientific
